Products
Dirlotapide is registered as an oral solution (Slentrol). It has been approved in many countries since 2008.
Structure and properties
Dirlotapide (C40H33F3N4O3, Mr = 674.7 g/mol) is an indole carboxamide and biphenyl derivative. It exists as a white crystalline powder that is soluble in water to <0.1 mg/ml.
Effects
Dirlotapide (ATCvet QA08AB91) is an inhibitor of the microsomal triglyceride transfer protein, which plays an important role in fat absorption in the intestine. Inhibition reduces fat absorption and lowers plasma cholesterol and triglyceride concentrations. Dirlotapide acts primarily locally in the digestive tract and only slightly systemically. It also has indirect appetite suppressant properties.
Indications
For the treatment of overweight and obesity in adult dogs. The drug is not approved for use in humans.
Dosage
According to the package insert.
Contraindications
Dirlotapide should not be used in hypersensitivity, in cats, in growing dogs, in pregnant or lactating bitches, and in hepatic dysfunction. For complete precautions, see the drug label.
Interactions
No information is available on interactions with other drugs.
Adverse effects
The most common possible adverse effects include vomiting, diarrhea, constipation, weakness, and ALT increase. In rare cases, behavioral changes have been reported.
